Log in to save to my catalogue

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_501969

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

About this item

Full title

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Publisher

United States: Massachusetts Medical Society

Journal title

The New England journal of medicine, 2016-10, Vol.375 (14), p.1319-1331

Language

English

Formats

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

The addition of daratumumab to lenalidomide and dexamethasone resulted in superior response rate and progression-free survival, as compared with lenalidomide and dexamethasone alone, at a cost of more frequent neutropenia and infusion reactions.
The incorporation of proteasome inhibitors and immunomodulatory drugs into the standard of care has i...

Alternative Titles

Full title

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_swepub_primary_oai_swepub_ki_se_501969

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_501969

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1607751

How to access this item